Trisha Bank
Family · Colorado Springs, CONPI 1023627429
Payments from drug & device makers
Across 188 payments — averaging $21.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$666
- Regeneron Healthcare Solutions, Inc.$408
- Mylan Specialty L.p.$289
- Boehringer Ingelheim$278
- Grifols USA, LLC$255
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,96999%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $1,041 |
| GSK | 37 | $666 |
| Regeneron Healthcare Solutions, Inc. | 20 | $408 |
| Mylan Specialty L.p. | 13 | $289 |
| Boehringer Ingelheim | 12 | $278 |
| Grifols USA, LLC | 17 | $255 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $251 |
| Actelion Pharmaceuticals US, Inc. | 5 | $109 |
| AbbVie | 4 | $85 |
| Viatris Specialty LLC | 4 | $78 |
| Baxter Healthcare | 3 | $55 |
| Pfizer | 3 | $53 |
| Amgen | 2 | $52 |
| Sanofi | 2 | $51 |
| United Therapeutics Corporation | 2 | $49 |
| Insmed, Inc. | 2 | $46 |
| Novartis | 2 | $41 |
| La Jolla Pharmaceutical Company | 1 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $30 |
| Genentech USA, Inc. | 1 | $24 |
| Pulmonx Corporation | 1 | $24 |
| Merck | 1 | $22 |
| Philips North America LLC | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,003 in reported general payments places this provider in the 90th percentile of 2,182 family providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 373 | $325,083 |
| Spiriva RespimatTiotropium Bromide | 173 | $132,163 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 135 | $107,224 |
| Dupixent PenDupilumab | 24 | $95,948 |
| Breo ElliptaFluticasone/Vilanterol | 144 | $75,373 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 105 | $61,277 |
| NucalaMepolizumab | 16 | $59,536 |
| XolairOmalizumab | 25 | $57,251 |
| Incruse ElliptaUmeclidinium Bromide | 71 | $33,870 |
| Arnuity ElliptaFluticasone Furoate | 139 | $31,947 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $31,851 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 165 | $29,232 |
| SymbicortBudesonide/Formoterol Fumarate | 60 | $24,520 |
| Advair HfaFluticasone Propion/Salmeterol | 48 | $18,292 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 413 | $17,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Arnuity Ellipta | $666 | $557,661810 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $278 | $193,441278 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,041 | $131,744195 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,182 family providers in Colorado.
Other family in Colorado Springs
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- Jeannette LillerColorado Springs$74K
- Jacquita JordanColorado Springs$52K
- Stephanie HanenbergColorado Springs$40K
- Barbara ChamnessColorado Springs$15K
- Julie UnruhColorado Springs$14K
- Lisa HutchcraftColorado Springs$13K
- Kristin SekelskyColorado Springs$10K
- Leandrea TzitzicasColorado Springs$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.